Indian Court Won't Block Generic Nexavar

Law360, New York (February 12, 2010, 4:16 PM EST) -- An Indian court has reportedly denied an appeal by Bayer AG that sought to block the sale of a generic version of its cancer drug Nexavar, the latest in a series of setbacks for branded-drug companies involved in patent disputes in the country.

The Delhi High Court on Tuesday dismissed an appeal by Bayer that had sought an order requiring the Drug Controller General of India to consider the patent status of drugs before granting marketing approval to any generics maker, The Wall Street Journal reported...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.